Sino-Singapore Jingwei, May 1 (Wan Keyi) As of April 30, according to the biological classification of A-share Shenwan Pharmaceuticals, 436 companies have disclosed their 2021 annual report data.

Flush iFinD data shows that among the 436 companies, 378 achieved profits and 58 lost money; in terms of performance growth, 259 companies’ revenue and net profit both increased year-on-year.

Nearly 90% of companies are profitable

  Sino-Singapore Jingwei noticed that during the reporting period, among the above-mentioned 436 pharmaceutical companies, 378 had positive net profits (hereinafter referred to as "net profits") attributable to owners of the parent company, accounting for 86.7%; Revenue and net profit both increased year-on-year, accounting for 59.4%.

  Among them, in 2021, Zhifei Bio’s net profit will be the highest among pharmaceutical companies, reaching 10.209 billion yuan, a year-on-year increase of 209.23%; revenue will be 30.652 billion yuan, a year-on-year increase of 101.79%.

  In terms of net profit growth, there are 69 companies with a year-on-year growth rate of more than 100%.

Among them, Jimin Medical, Rejing Bio, Lisheng Pharmaceutical, and Harbin Sanlian increased by 2206.02%, 1850.41%, 1317.31% and 1096.77% respectively.

  Sino-Singapore Jingwei noted that excluding 58 loss-making companies, another 112 had a year-on-year decrease in net profit in 2021.

The largest decline was Jiaying Pharmaceutical, which fell by 92.55% year-on-year.

Seven companies including Yuheng Pharmaceutical, Yangpu Medical, Meinian Health, Yao.com, Lexin Medical, Fuxiang Pharmaceutical, and Baolite also fell by more than 80%.

  New latitude and longitude in the data map

  Among them, Jiaying Pharmaceutical explained that this year, Jiaying Pharmaceutical made a full provision for impairment of 28.7993 million yuan for Guangdong Kangci Medical Development Co., Ltd. The book balance of long-term equity investment accounts for 48.49% of the ending balance of the company's long-term equity investment, and the provision for asset impairment losses has a greater impact on Jiaying Pharmaceutical's net profit this year.

  In terms of Meinian Health, compared with a huge loss of 866 million yuan in 2019 and a non-net profit loss of 600 million yuan in 2020, although the company's performance in 2021 has improved, it still "increases revenue but not profit."

  It is worth mentioning that Meinian Health’s large-scale acquisitions have also accumulated high goodwill.

As of the end of last year, the book value of the company's goodwill was 4.051 billion yuan.

Meinian Health mentioned in its annual report that according to the relevant provisions of the Accounting Standards for Business Enterprises, goodwill is not amortized, but it needs to be tested for impairment at the end of each year in the future.

During the preparation of the annual report in the future, the company will perform the goodwill asset impairment assessment test process.

  Meinian Health also pointed out that in its daily operations, it cannot be ruled out that the acquired company does not meet the expected earnings after the acquisition, and there is a risk of goodwill impairment.

The impairment of goodwill will directly affect the company's operating performance and reduce the company's current profits.

BeiGene Becomes "Loss King"

  In 2021, from the net profit of the above-mentioned 436 companies, 58 will suffer losses.

BeiGene, which lost more than 9.7 billion yuan, has become the industry's "loss king", but the year-on-year loss has narrowed.

  BeiGene stated in its annual report that the company was not profitable and had accumulated losses during the reporting period. The main reason was that most of the company's product pipeline was still in the stage of new drug research and development, and sales had not yet been formed, and the amount of research and development expenditure was large. This situation is in line with new drug research and development enterprises The specific reasons are: the company has been focusing on drug research and development since its establishment, with a large number of research and development pipelines, and the research and development expenses showed an increasing trend during the reporting period; the company sold 3 self-developed drugs and 5 authorized products during the reporting period. The sales revenue cannot cover the costs and expenses.

  Sino-Singapore Jingwei also noticed that the net profit of International Medicine, Bohui Innovation and Guangyuyuan decreased by more than 1000% year-on-year last year, with a decrease of 1912.52%, 4393.41% and 1008.17% respectively, and their net losses were 822 million yuan and 322 million yuan respectively. , 316 million yuan.

In addition, the above three companies are all from profit to loss.

  The drop in net profit of Bohui Innovation by more than 4,000% is staggering. When it comes to the reasons for the loss in performance, the company said that firstly, the company’s subsidiary company, Zhongke Biotechnology, stopped production and transformation, resulting in a sharp drop in revenue and a large amount of losses due to suspension of work; The suspension of production and transformation of Biotech and the approval of the operating qualifications for the establishment of a pulp station under Sino Biotech were lower than expected. Hebei Daan, a subsidiary of the company, made an impairment on the goodwill formed by its acquisition of Sino Biotech according to the asset evaluation report issued by the appraisal agency. preparation; third, the company has increased external liabilities and financial expenses in order to support the construction of the blood product production base in Qujing, Yunnan; fourth, the company has further increased research and development expenditures.

  However, Bohui Innovation said that the loss is not sustainable, and there is no major risk to the company's ability to continue operating.

Which one is stronger in R&D?

  In the era of innovation, the importance of R&D personnel to pharmaceutical companies is obvious.

The amount of R&D investment and R&D personnel represents the innovation capability of pharmaceutical companies to a certain extent.

  Flush iFinD data shows that 429 of the 436 pharmaceutical companies mentioned above have announced their R&D numbers in 2021.

Among them, WuXi AppTec has the largest number of R&D personnel, reaching 28,841; Pharmaron also has more than 10,000 people, reaching 13,455.

In addition, there are 3 companies with more than 5,000 R&D personnel, namely International Medicine, Hengrui Medicine, and *ST Hengkang.

  Ho's Ophthalmology Department has the smallest number of R&D personnel, and its R&D personnel in 2021 will only be 3.

In addition, Dali Medicine and *ST Jintai have less than 10 R&D personnel, 8 and 6 respectively.

  In terms of the proportion of R&D personnel, Pharmaron has the highest proportion, reaching 90.16%.

In 2021, companies with more than 80% of R&D personnel also include Medicilon, Shouyao Holding, International Medicine, Chengdu Pioneer, WuXi AppTec, Sunshine Novo, and *ST Baihua.

Among the 106 listed companies with R&D personnel accounting for less than 10%, including Guangyuyuan, Tigermed, Winbond Health, Fosun Pharma, and Shanghai Pharmaceuticals, the proportion of heavy pharmaceutical holdings is the lowest, and the annual report shows 0.

  In terms of R&D investment, Flush iFinD shows that 423 of the 436 companies mentioned above disclosed this data in 2021, with a total of 96.458 billion yuan; in comparison, 426 companies disclosed R&D investment in 2020, with a total of 83.425 billion yuan.

  Among them, in 2021, BeiGene will invest the most in R&D, reaching 9.538 billion; Hengrui Medicine and Fosun Pharma will rank second and third respectively, with R&D investment of 6.203 billion and 4.975 billion; 220 of them have less than 100 million R&D investment. Company, *ST Hengkang the least, was 444,000 yuan.

  Compared with 2020, the top 20 companies with R&D investment will all increase in 2021.

Hengrui Medicine’s R&D investment increased the most, with an increase of 1.214 billion yuan over 2020; BeiGene, Fosun Pharma, Mindray Medical, Shanghai Pharmaceuticals, Joincare, and Livzon Group all increased their total R&D investment by over 500 million yuan.

  In terms of the ratio of R&D investment to revenue, Dizhe Pharmaceuticals ranked first with 5,712.89%, and Maiwei Bio and First Pharmaceutical Holdings also reached 3,836.47% and 1,203.46%, respectively.

The lowest proportion is *ST Hengkang, which is 0.0147%

  It should be mentioned that the total R&D investment of 148 pharmaceutical and biological companies in 2021 will decrease compared with 2020, and the proportion of Alice will drop from 31,728.84% in 2020 to 41.99% in 2021.

BeiGene dropped from 421.78% in 2020 to 125.69% in 2021.

  In this regard, Ellis said that the main reason was that the operating income generated by the domestic listing and overseas authorization of fumetinib during the reporting period increased significantly compared with the same period of the previous year, and the operating income base of the previous year was relatively small.

BeiGene also explained that the ratio of R&D investment to operating income has decreased compared with the same period of the previous year, mainly due to the high growth rate of the company's operating income during the reporting period.

(Sino-Singapore Jingwei APP)

(The opinions in this article are for reference only and do not constitute investment advice. Investment is risky, and you need to be cautious when entering the market.)

All rights reserved by Sino-Singapore Jingwei. Without written authorization, no unit or individual may reproduce, extract or use in other ways.

Keywords: